learndrugs
Nervous

Multiple Sclerosis

MS Verified · Sep 2026

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which inflammation destroys myelin, injures axons, and scars (gliosis) the brain, optic nerves, and spinal cord, slowing or blocking the messages between the brain and the body.

The disorder behind optic neuritis and the afferent pupillary defect, Lhermitte’s electric shock, Uhthoff’s heat rule, the relapse-versus-pseudo-relapse question every nurse must ask before steroids, the baclofen never-stop-abruptly warning, and the PML watch on disease-modifying therapy.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 An immune attack on central myelin — the plaque

MS begins outside the brain. An unknown antigen activates Th1 and Th17 T cells, which attach to the endothelium of CNS vessels and cross the blood-brain barrier; innate cells (monocytes, macrophages) drive that migration, and the crossing itself injures the barrier so more immune cells pour in. Where the inflammation focuses, a macroscopic plaque forms — the MS lesion — built of myelin loss, edema, and axonal injury. Plaques cluster around small veins and venules with sharp margins, which is why a vein runs through the center of a typical lesion on MRI, and while the barrier is open the lesion enhances with gadolinium — the imaging signature of an active attack.

This is not a pure white-matter disease. Plaques strike the periventricular and juxtacortical white matter, the optic nerves, spinal cord, cerebellum, cortical gray matter, and even the meninges, and widespread cortical demyelination is a major contributor to progressive disability. B cells matter too: antibody production and meningeal B-cell follicles are linked to early-onset disease — the rationale for anti-CD20 therapies that deplete B cells.

Downstream, the cascade runs demyelination → neuroaxonal degeneration, synapse loss, dying-back oligodendrocyte injury, and astrogliosis. Repair happens — remyelinated plaques show thinly myelinated axons and oligodendrocyte precursor cells, and neural plasticity explains why symptoms do not always match the MRI — but repair is incomplete. Long-term disability is the sum of incomplete recoveries: each relapse leaves a little behind, and the deficits accumulate.

The plaque: T cells breach the blood-brain barrier, a perivenular lesion strips myelin and injures axons, repair is partial, and each incomplete recovery adds to disability.

02 Why a demyelinated nerve stops talking — and why heat matters

Myelin lets an action potential jump efficiently along the axon with a wide safety factor — far more current than the next segment needs. Demyelination reduces that safety factor toward the edge of failure, so the fiber conducts slowly, or not at all. The patient-language version is exact: the damage slows down or blocks messages between the brain and the body, and every MS symptom is some circuit slowing or blocking.

That thin margin explains the most testable phenomenon in MS. A rise in core temperature of as little as 0.2–0.5 °C is enough to close the axonal sodium channel on a demyelinated segment and abort the action potential. So fever, hot weather, a hot shower, a sauna, exercise, even a hot meal or psychological stress can make old deficits reappear — blurred vision, weakness, numbness — for less than 24 hours, resolving within minutes to an hour once heat exposure stops or cooling begins. This is the Uhthoff phenomenon, present in 60–80% of people with MS, and it is not new damage: the lesion was already there; the temperature merely unmasked it.

The pharmacology proves the mechanism. Dalfampridine, a potassium-channel blocker, restores conduction in focally demyelinated axons and improves walking in a subset of patients — a drug that treats the conduction failure without touching the immune attack.

Conduction failure: demyelination erodes the safety factor, a fraction of a degree closes sodium channels, and cooling reopens the circuit — the Uhthoff phenomenon.

03 The courses: RRMS, SPMS, PPMS — and the first attack (CIS)

Relapsing-remitting MS (RRMS) is the most common form, seen in 70–80% of patients: new or recurrent neurological symptoms develop over days to weeks, then show partial or complete recovery over weeks or months. Mean onset is 25–29 years. Secondary progressive MS (SPMS) follows an initial relapsing course: the decline becomes gradual, and superimposed relapses can still occur but are not required. Primary progressive MS (PPMS), in 15–20%, deteriorates gradually from the start without relapses and begins later, around 39–41 years.

A clinically isolated syndrome (CIS) is a single episode of inflammatory CNS demyelination — a first attack such as optic neuritis without proof yet of dissemination in time; it is the precursor to definite MS. (A radiologically isolated syndrome is MS-typical MRI findings with no symptoms at all; only about a third of those people are diagnosed with MS within 5 years.)

The phenotype predicts what treatment can do. Relapsing disease is inflammation-driven, so therapies that block immune cells reduce relapses and MRI activity. Progressive disease is driven mainly by neurodegeneration, and disease-modifying therapies show only possible-to-limited benefit there — younger patients with a shorter duration of progression tend to benefit more. The disorder is life-long and incurable, yet life expectancy can be normal or almost normal; symptoms accumulate over 10–15 years, and a relapsing course with mild relapses, good recovery between attacks, and a low MRI lesion load carries the better prognosis.

04 Relapse versus pseudo-relapse — the definition the nurse acts on

A relapse is an event typical of acute inflammatory demyelination — new or worsening symptoms lasting at least 24 hours, separated by at least 30 days from the prior event, in the absence of fever or infection. That last clause is the whole exam. A pseudo-relapse is a temporary worsening of old symptoms caused by something systemic — infection, fever, heat exposure, exertion — that improves when the underlying condition resolves. Uhthoff-type symptoms fade within minutes to an hour of cooling; a true relapse persists for days.

Infection is the everyday trigger of both. During an infection the risk of a true relapse roughly doubles (RR 2.07), and pseudo-relapses cluster with infection — present in about 30% of people with a recent infection versus 19% without, most within a month. Urinary tract infection and respiratory infection are the usual culprits, and a hidden UTI in a patient with a neurogenic bladder often announces itself not as burning but as more spasms, worse weakness, or confusion.

Getting this right is a safety decision. The work-up before anyone says "relapse" is a neurological exam plus CBC, electrolytes, and urinalysis to screen for infection, and MRI with gadolinium-enhancing lesions to show recent inflammatory activity. Misreading a pseudo-relapse as a relapse leads to inappropriate steroids or an unnecessary switch of disease-modifying therapy; for a pseudo-relapse the target is the underlying illness. Even genuine relapses are often mild enough to observe — in a large registry, 97.7% were untreated with corticosteroids.

The fork every relapse call passes through: fever, infection, or heat means pseudo-relapse and treat the cause; no fever and symptoms beyond 24 hours means a true relapse, imaged and treated with steroids and, if unresponsive, plasma exchange.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Female sex — about 3-fold more common than in males Onset age 20–40 (RRMS mean 25–29; PPMS 39–41); almost 10% present before age 18 Epstein-Barr virus infection — 32-fold higher risk after seroconversion; likely a prerequisite for disease, compounded by severe infectious mononucleosis HLA-DRB1*1501 allele — the most established genetic risk factor First-degree relative with MS (2–4% risk vs 0.1% general population); monozygotic twin concordance 20–30% Northern European ancestry (about 1 in 1,000) and higher latitude — a prevalence gradient toward northern Europe and North America Lack of sun exposure & vitamin D deficiency, especially in childhood and adolescence modifiable Smoking & secondhand smoke — raises the risk of developing MS and of faster progression to SPMS (not a relapse trigger) modifiable Obesity in childhood and adolescence modifiable Low vitamin D once diagnosed — weakly but consistently associated with higher disability scores and relapse modifiable

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Optic neuritis — monocular vision loss over hours to days, pain on eye movement, washed-out reds, relative afferent pupillary defect (RAPD) early Hold & notify
Why: Autoimmune demyelination of the optic nerve with perivascular T-cell and macrophage infiltration. Pain often precedes the visual loss; the fundus is normal in retrobulbar neuritis or swollen in papillitis. Optic neuritis precedes MS in 15–20% of cases and about half of people with MS have had an attack. New vision loss is a same-day report.
Diplopia or blurring on lateral gaze — internuclear ophthalmoplegia (INO) Hold & notify
Why: A lesion of the medial longitudinal fasciculus in the brainstem: the eye on the side of the lesion cannot adduct while the other eye shows nystagmus as it abducts — with convergence preserved. Often bilateral in MS; nearly half resolve within a year. New diplopia signals a new lesion and is reported.
Numbness, pins-and-needles, dysesthesias, and a band-like squeeze around the chest or abdomen early
Why: Demyelination of the dorsal columns and spinothalamic tracts distorts or drops sensory traffic; the truncal band (the "MS hug") is a spinal-cord sensory level in disguise.
Lhermitte sign — an electric shock down the spine and limbs on neck flexion Expected
Why: Demyelination of the dorsal columns of the cervical cord makes the fibers mechanosensitive, so stretching them with neck flexion fires them. Seen in 9–41% of people with MS, also provoked by fatigue, heat, and stress; mostly self-resolving.
Weakness — hemiparesis, monoparesis, or paraparesis — with hyperreflexia
Why: Corticospinal (upper motor neuron) demyelination cuts descending drive to the anterior horn; the loss of descending inhibition is what makes the reflexes brisk.
Spasticity — velocity-dependent stiffness, spasms, clonus
Why: Loss of descending supraspinal inhibition over spinal stretch reflexes; affects 37–78% of people with MS and is graded on the Modified Ashworth Scale (0–4). Some tone is useful — it can allow standing and weight-bearing that protects bone and circulation — so the goal is function, not zero tone.
A sudden jump in spasms or weakness with fever, dysuria, cloudy or foul urine, or confusion Hold & notify
Why: Infection and fever raise core temperature and unmask old lesions (pseudo-relapse), and in spinal cord disease increased spasticity is an atypical presentation of UTI. Constipation, pressure sores, and ingrown toenails do the same. Assess for the hidden trigger before calling it a relapse.
Ataxia, intention tremor, dysarthria, vertigo, dysphagia Hold & notify
Why: Cerebellar and brainstem plaques disrupt coordination of movement and speech; cerebellar tremor can be profoundly disabling (wrist weights may help unless weakness precludes them). Any sign of swallowing trouble at meals is reported — "Chronic dysphagia due to bulbar dysfunction can lead to chronic aspiration."
Urinary frequency, urgency, urge incontinence ± incomplete emptying
Why: Neurogenic bladder in 40–90% of people with MS: sacral-pathway demyelination causes detrusor hyperreflexia (50–90%), and detrusor-sphincter dyssynergia can make both storage and emptying fail, leaving an elevated post-void residual that breeds infection.
Constipation (the most frequent GI complication); sexual dysfunction
Why: The same autonomic and spinal pathway injury slows bowel transit and disrupts erectile and sexual function; constipation itself aggravates spasticity.
Fatigue — a lack of physical and mental energy, often unrelieved by rest
Why: Affects more than 75% of patients and is called the worst symptom by more than half. Primary drivers: CNS inflammation, demyelination, axonal loss, and HPA-axis dysregulation; secondary drivers: poor sleep (including sleep apnea), depression, medications, and inactivity — the secondary layer is the treatable one.
Memory and executive-function impairment, poor concentration; depression and anxiety
Why: Cortical gray-matter demyelination and atrophy underlie the cognitive changes; depression is listed first among complications and is strongly intercorrelated with fatigue, sleepiness, and disability — screen for it at every visit.
Heat sensitivity — symptoms worsen in hot weather, after a hot shower, or with exercise (Uhthoff) Expected
Why: A 0.2–0.5 °C rise in core temperature closes sodium channels on demyelinated axons and blocks conduction; symptoms last under 24 hours and resolve within minutes to an hour of cooling. Expected — and the reason for the cooling plan — not a new lesion.
Deficits that develop within minutes, seizures, aphasia or neglect, onset before 10 or after 50 Report immediately
Why: These are red flags against MS. MS symptoms build over days to weeks; a deficit that arrives in minutes points to a vascular event and is worked up as a stroke, not a relapse.

Diagnostics

Test In this disorder Normal
MRI brain & spinal cord with gadolinium The diagnosis rests on dissemination in space — lesions in at least 2 of 5 typical sites (periventricular, cortical/juxtacortical, infratentorial, spinal cord, and, new in 2024, optic nerve; the 2017 revision used four) — and dissemination in time: new T2 lesions on follow-up, enhancing plus non-enhancing lesions on one scan, or a second clinical attack. In 2024, DIT is no longer required for every patient; lesions in 4 of 5 sites, positive CSF, a central-vein sign, or a paramagnetic rim lesion can substitute. Cord lesions in MS are short and focal; a lesion spanning 3 or more segments points to NMOSD T2-hyperintense lesions (T1 iso/hypointense "black holes") with a periventricular predilection, Dawson fingers perpendicular to the ventricles, and gadolinium enhancement where the blood-brain barrier is actively broken 2024 McDonald criteria (Solomon et al., Neurology 2026) —
CSF oligoclonal bands (lumbar puncture) Positive CSF has counted as proof of dissemination in time since 2017. Bands are not specific — raised CSF IgG can also reflect a CNS infection or another inflammatory or autoimmune disease (the MS differential includes Lyme disease and HIV), which is why positive bands never diagnose MS alone. Classic MS CSF: elevated protein and myelin basic protein, a few mononuclear cells, raised IgG ≥ 2 CSF-restricted bands (present in CSF, absent in blood) = positive CSF; alternatively an intrathecal kappa free-light-chain index ≥ 6.1 2024 McDonald criteria Fewer than 2 CSF-restricted bands
CSF IgG index Often ordered with the bands, but a CSF IgG test alone cannot diagnose MS; a high index may equally mean infection or another inflammatory or autoimmune CNS condition Elevated — intrathecal antibody production —
Visual, brainstem & somatosensory evoked potentials Supportive only: evoked potentials were dropped from the McDonald criteria and cannot establish dissemination. Teach them as evidence of slowed conduction, not as a diagnostic test Slowed conduction in pathways the patient has never noticed — subclinical involvement —
AQP4-IgG & MOG-IgG serum antibodies Ordered when features are atypical — bilateral or posterior optic neuritis, a long cord lesion, unexplained hiccups, nausea, or vomiting (area postrema syndrome). Getting this right matters because natalizumab, beta-interferon, and fingolimod can worsen NMOSD; misdiagnosis of MS runs about 15% at subspecialty centers Negative in MS; positive AQP4-IgG (60–90% of NMOSD) redirects the diagnosis —
Relapse work-up: CBC, electrolytes, urinalysis ± culture Drawn before any relapse is labeled: a relapse is defined in the absence of fever or infection. White-cell casts suggest renal involvement; in a catheterized patient the culture threshold is 1,000 CFU/mL (IDSA definition as carried by StatPearls). Misdiagnosis here leads to inappropriate steroids or DMT changes Normal in a true relapse; leukocytes, nitrites, and bacteria on urinalysis (with or without fever) unmask a UTI-driven pseudo-relapse —
Post-void residual (bladder scan) ± urodynamics Reviewed periodically — and re-checked after starting anticholinergics, because people with MS are the most likely to develop retention on them Elevated residual with incomplete emptying; sustained bladder pressures > 40 cm H₂O on urodynamics threaten the upper urinary tract —

Complications

Caution: Urinary tract infection — the complication that feeds back into relapse Hold & notify
Fever, burning when urinating, bad-smelling or cloudy urine, frequent urges to urinate, back or side pain below the ribs — or, in a neurogenic bladder, just more spasms, more weakness, or new confusion.
Incomplete emptying and catheter use make UTI the recurring infection of MS, and infection doubles relapse risk while also driving pseudo-relapses through fever. Treat symptomatic infection promptly; avoid indwelling catheters whenever possible and remove them as soon as feasible; do not give routine prophylactic antibiotics to permanently catheterized patients — treat symptomatic infection.
Warning: Progressive multifocal leukoencephalopathy (PML) on disease-modifying therapy Report immediately
Subacute, progressive new hemiparesis, clumsiness, visual changes, memory or thinking changes, personality change, gait or limb ataxia, hemianopia, aphasia.
A JC-virus infection of the brain that is progressive and fatal, classically on natalizumab — risk stratified by anti-JCV antibody status, treatment beyond 2 years, and prior immunosuppression (0.09 vs 11.1 cases per 1,000), dispensed only through the TOUCH program — and watched for on ocrelizumab and other immunosuppressive DMTs. Management is stopping the drug and plasma exchange. A new progressive deficit on a DMT is not assumed to be a relapse.
Warning: Baclofen withdrawal — abrupt stop Report immediately
Oral: seizures and hallucinations. Intrathecal pump: high fever, altered mental status, muscle rigidity, and severe rebound spasticity that can progress to rhabdomyolysis and multi-organ failure.
Baclofen is a GABA-B agonist; remove it suddenly and the spinal reflexes it was suppressing fire unopposed. Drug holidays happen only in hospital with a 2–4 week taper; pump patients keep every refill appointment and monitor the pump. Tizanidine has its own rebound — tachycardia, hypertension, and increased spasticity — and is also tapered.
Caution: Rebound and teratogenicity when disease-modifying therapy stops Hold & notify
Stopping fingolimod, siponimod, ozanimod, or natalizumab abruptly invites rebound — relapses in about 30% within six months of stopping fingolimod.
Teriflunomide, cladribine, fingolimod, siponimod, and ozanimod are teratogens, so pregnancy must be planned with the neurologist: washouts (fingolimod ≥ 2 menstrual cycles, natalizumab 3 cycles), teriflunomide either stopped 2 years before conception or accelerated-elimination, and glatiramer or interferon as the usual continue-or-stop-at-conception options.
Caution: Immobility’s cascade — falls, pressure sores, osteoporosis, aspiration
Mobility disability reaches up to 90% of patients within ten years; walking is the function people with MS value most.
Postural instability and spasticity set up falls; immobility breeds pressure sores where bone lies close to the skin — ankles, heels, hips, elbows and back (which then aggravate spasticity), osteoporosis from lost weight-bearing, catheter dependence, and aspiration from dysphagia. Depression and cognitive decline limit self-care and compound all of it.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Corticosteroids First-line
Endocrine · prednisone

The acute relapse drug, not a maintenance drug: high-dose IV methylprednisolone (500–1,000 mg daily for 3–7 days, optionally with a short prednisone taper) is the preferred first-line treatment, and high-dose oral prednisone at equivalent doses gives equivalent outcomes. Steroids accelerate recovery but do not change long-term disability — the final vision after optic neuritis is no better with steroids than without — and low-dose oral prednisone alone increases recurrent optic neuritis. They are reserved for true relapses: rule out fever and infection first, because in a pseudo-relapse the target is the underlying illness. Poor response → plasma exchange, daily or alternate days for 3–7 treatments.
Immunosuppressants / Biologics / DMARDs
Immune / Anti-infective · methotrexate

The disease-modifying therapies (DMTs) are immunosuppressants and immunomodulators aimed at fewer relapses, less MRI activity, and less permanent disability — started promptly at diagnosis — "Immediate treatment initiation upon diagnosis is crucial" (StatPearls) — with the agent chosen by disease activity and safety profile (ECTRIMS/EAN 2018), and considered even for CIS with an abnormal MRI (ECTRIMS/EAN 2018). Classes: injectable interferon-beta (flu-like symptoms 2–8 h after injection; LFT and CBC every 6 months) and glatiramer (post-injection flushing, dyspnea, palpitations that self-resolve in 30 minutes; rotate sites to limit lipoatrophy); oral S1P modulators such as fingolimod (first-dose bradycardia at 4–6 h → observed initiation; macular edema check; VZV immunity screened; rebound on stopping); IV natalizumab (anti-α4-integrin; PML risk by JCV status and duration); IV anti-CD20 ocrelizumab (infusion reactions in a third → premedication; hepatitis B screening; the first therapy approved for PPMS); oral cladribine (TB/HBV/HIV screening; herpes risk; teratogen). Class-wide rules: delay infusions during active infection, complete live vaccines before starting (≥ 4 weeks; 6 weeks for ocrelizumab), and teach the PML warning signs.
Skeletal Muscle Relaxants First-line
Musculoskeletal · cyclobenzaprine

For spasticity from lost descending inhibition — baclofen (GABA-B agonist; first-line oral agent, intrathecal for severe unresponsive spasticity; avoid at eGFR ≤ 30) and tizanidine (central α2-agonist; hypotension, dry mouth, hepatotoxicity → LFTs; avoid ciprofloxacin and fluvoxamine). They relieve tone and spasm but have not been shown to improve function on their own, and the sedation and weakness can strip away the useful tone a patient stands on — so dose to function, pair with stretching and PT, and treat aggravating factors (UTI, constipation, skin lesions, pain) first. Never stop abruptly: oral baclofen withdrawal causes seizures and hallucinations, intrathecal withdrawal a hypermetabolic crisis, tizanidine withdrawal rebound hypertension and tachycardia.

Beyond medications

  • Rehabilitation as therapy — physical, occupational, and speech therapy, assistive devices, and structured exercise (walking, stationary cycling, resistance work, yoga, Pilates) give small but clinically meaningful gains in walking, and improve balance, sleep, and mood — people with MS are advised to "stay as active as you comfortably can."
  • Dalfampridine for walking — a potassium-channel blocker (10 mg twice daily) that restores conduction in demyelinated axons; about 38% respond on the timed 25-foot walk versus 9% on placebo. It causes dizziness, insomnia, balance problems, and falls, raises seizure risk at higher doses, and is contraindicated in renal impairment.
  • Fatigue program, non-drug first — aerobic and resistance exercise, cognitive behavioral therapy, and treatment of sleep disorders (including sleep apnea), depression, and metabolic comorbidities are the evidence-backed layer. Amantadine and modafinil are commonly used off-label with mixed, weak evidence: the largest crossover trial found neither beat placebo, and both add adverse effects (amantadine — orthostasis, hallucinations, livedo reticularis; modafinil — severe rashes within six weeks and reduced hormonal-contraceptive efficacy).
  • Spasticity without drugs — daily stretching and range of motion, positioning, splinting or serial casting, heat and cold therapy; treat the aggravators (UTI, constipation, calculi, pressure sores, ingrown toenails, pain). Botulinum toxin and an intrathecal baclofen pump are reserved for refractory cases.
  • Bladder program — anticholinergics for detrusor overactivity with repeat post-void residual checks (people with MS are the most likely to develop retention on them); pelvic-floor physiotherapy, especially for women; desmopressin for nocturnal polyuria; botulinum toxin or sacral neuromodulation when refractory. When a urinary catheter is needed, avoid indwelling catheters whenever possible and remove them as soon as feasible.
  • Plasma exchange (PLEX) — for severe relapses with a poor glucocorticoid response: daily or alternate-day treatments, 3–7 in total. ACTH gel and IVIG are second-line alternatives; IVIG is preferred for relapses in the first trimester of pregnancy.
  • Persistent diplopia — Fresnel prisms or botulinum toxin injections; chronic vertigo may respond to meclizine, ondansetron, or diazepam. Lifestyle: smoking cessation, vitamin D supplementation, balanced diet, and connecting with supportive people.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
For any new or worsening symptom, ask the relapse questions first: fever? infection? heat exposure? exertion? lasting ≥ 24 hours? — then check temperature, urinalysis/culture, CBC, and electrolytes.
Why: A relapse is defined in the absence of fever or infection; pseudo-relapses cluster with infection and resolve when the cause is treated. Steroids or a DMT switch for a pseudo-relapse is the documented inappropriate treatment.
Assess vision (acuity, color, pain on eye movement, pupils for an afferent defect) and eye movements (adduction on lateral gaze) with every neuro check.
Why: Optic neuritis and INO are the classic MS attacks — new monocular vision loss or new diplopia means a new lesion and is reported the same day.
Grade spasticity (Modified Ashworth 0–4), strength, coordination, and gait each shift; treat a sudden rise in spasms as a possible hidden infection, constipation, or skin lesion.
Why: In spinal cord disease increased spasticity is an atypical presentation of UTI; the aggravating factor, not the baclofen dose, is usually the fix.
Screen bladder function — voiding pattern, urgency, incontinence — and check a post-void residual, especially after anticholinergics are started.
Why: Elevated residuals breed the UTIs that trigger relapses and pseudo-relapses; anticholinergics relieve urgency but people with MS are the most likely to retain on them.
On pulse steroids, monitor blood glucose, blood pressure, potassium, sleep, mood, and GI symptoms; watch for infection.
Why: High-dose methylprednisolone causes hyperglycemia, hypertension, hypokalemia, insomnia, mood change, psychosis, gastritis, and infection susceptibility — the toxicities are predictable, so surveillance is scheduled, not incidental.
On disease-modifying therapy, know the drug-specific watch: S1P modulator first-dose bradycardia at 4–6 h, natalizumab PML signs, ocrelizumab infusion reactions, interferon LFT/CBC — and screen for depression at every encounter.
Why: Each DMT class has one toxicity the nurse is positioned to catch first; depression is the most common psychiatric complication and travels with fatigue and disability.
Interventions & safety
Cool the patient who is heat-sensitive: avoid hot showers, hot baths and saunas; use cold showers, ice packs and cooling devices; schedule exercise for the cooler early-morning and late-evening hours; treat fever promptly.
Why: A 0.2–0.5 °C rise in core temperature blocks conduction in demyelinated axons; symptoms resolve within minutes to an hour of cooling — the fastest "treatment" in MS.
Treat symptomatic UTI promptly; avoid indwelling catheters whenever possible and remove them as soon as feasible; no routine prophylactic antibiotics for permanently catheterized patients.
Why: Infection doubles relapse risk and drives pseudo-relapses; catheters are the main source of complicated UTI in a neurogenic bladder.
Give baclofen and tizanidine on schedule and never let a dose lapse abruptly; on admission reconcile whether the patient has been skipping doses; taper only under orders (inpatient, 2–4 weeks for holidays).
Why: Abrupt baclofen withdrawal causes seizures and hallucinations — or, with a pump, hyperpyrexia, rigidity, and rebound spasticity that can end in rhabdomyolysis; tizanidine withdrawal brings rebound hypertension and tachycardia.
Run fall precautions: gait aids within reach, and physical and occupational therapy for movement, strength and daily activities; extra caution when sedation from baclofen or tizanidine, or dizziness from dalfampridine, is in play.
Why: Postural instability, weakness, spasticity, and drug sedation stack; dalfampridine itself lists falls among its adverse effects.
Inspect skin daily in the mostly immobile patient — ankles, heels, hips, elbows and back — and reposition; assess swallowing, since dysphagia raises the risk of aspiration.
Why: Pressure sores both result from immobility and aggravate spasticity; dysphagia leads to aspiration.
Hold DMT infusions during active infection per protocol; premedicate ocrelizumab as ordered (methylprednisolone and an antihistamine 30 minutes before); observe vital signs through S1P-modulator initiation.
Why: Infusing an immunosuppressant into an active infection deepens it; infusion reactions hit over a third of ocrelizumab patients, and first-dose bradycardia peaks 4–6 hours after fingolimod.
Patient teaching
Report new neurological symptoms lasting more than 24 hours — and, separately, infection cues: fever, burning when urinating, bad-smelling or cloudy urine, frequent urges to urinate, back or side pain, or a sudden jump in spasms.
Why: A symptom past 24 hours may be a relapse needing steroids; an infection needs treatment and explains a flare. Teaching both lets the patient tell them apart.
Manage fatigue with exercise, cognitive behavioral therapy, sleep and mood treatment, and activity planned for cooler, higher-energy parts of the day.
Why: Fatigue affects more than 75% of patients and is often unrelieved by rest; the non-drug measures carry the evidence, while amantadine and modafinil have mixed results and added side effects.
Never stop baclofen or tizanidine on your own; keep intrathecal pump refill appointments; report hallucinations, seizures, high fever with rigidity, or a racing heart with high blood pressure; no alcohol or benzodiazepines stacked on tizanidine.
Why: Withdrawal from either drug is dangerous, and the pump running dry is a medical emergency; sedatives compound the sedation and fall risk.
Injectable DMTs: rotate glatiramer sites among arms, abdomen, hips, and thighs; expect (and wait out) the 30-minute post-injection flush, dyspnea, or palpitations; expect interferon flu-like symptoms 2–8 hours after injection; report site infection or skin breakdown.
Why: Site rotation prevents lumps and lipoatrophy; knowing the reactions are self-limited stops a frightening but benign event from ending adherence — and adherence to DMT is what holds relapses down.
Vaccines: stay current (influenza, pneumococcal, tetanus-diphtheria, hepatitis B, zoster, COVID-19 and others); get live vaccines before most DMTs start (≥ 4 weeks; 6 weeks for ocrelizumab or alemtuzumab; inactivated ≥ 2 weeks); postpone live vaccines for 1 month during high-dose steroids; delay vaccination during a relapse until stable.
Why: DMTs blunt vaccine responses and make live vaccines unsafe, but vaccines do not raise relapse risk (ECTRIMS/EAN 2023) — infection does, so protection matters more, not less.
Pregnancy planning with the neurologist: fertility is not reduced, relapses fall during pregnancy and rise postpartum (the best predictor is the pre-pregnancy relapse rate); several DMTs are teratogens or rebound when stopped; connect with supportive people.
Why: Unplanned DMT stops risk rebound; teratogenic agents need washouts or elimination procedures; glatiramer and interferon are the usual continue-or-stop-at-conception choices, and connecting with supportive people helps with the emotional load of a chronic illness.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues that matter: three days of worsening leg weakness, spasms, and right-eye blur — new relative to baseline — in a patient with fever (38.3 °C), tachycardia, dysuria, and a urinalysis full of nitrites, leukocyte esterase, and bacteria on top of a 210 mL post-void residual. Add the context: five days without air conditioning in July, and several missed baclofen doses. The noise: the SpO₂ and blood pressure are unremarkable, and the eye exam shows no pain on movement and no afferent pupillary defect — the blur does not have the signature of a new optic neuritis.

  2. 2
    Analyze cues

    Apply the definition: a relapse is new or worsening symptoms lasting ≥ 24 hours in the absence of fever or infection. She has both, plus heat. That makes this, until proven otherwise, a pseudo-relapse — old lesions unmasked because a fraction of a degree of core temperature closes sodium channels on demyelinated axons and blocks conduction. The UTI is also a classic aggravator of spasticity, and in spinal cord disease increased spasticity is an atypical presentation of UTI. The missed baclofen is a second, independent driver of spasms — and a safety issue, because abrupt withdrawal can produce seizures and hallucinations. The honest caveat: infection also doubles the risk of a true relapse, so this is not settled; it is sequenced. Treat the infection and the heat, restore the baclofen, and see what deficit remains.

  3. 3
    Prioritize

    Priority one is the infection and the temperature: antibiotics on time, antipyretics, and active cooling — these are the interventions that both treat the pseudo-relapse and remove a relapse trigger. Priority two is baclofen safety: resume the scheduled dose now and watch for withdrawal signs. Priority three is protection while she is weak: fall precautions and bladder care (she has a 210 mL residual with an infection — no indwelling catheter unless unavoidable). Steroids are deliberately not on the list: giving high-dose methylprednisolone into an active infection would add immunosuppression, hyperglycemia, and insomnia without changing her long-term disability even if this were a relapse. The patient’s question deserves a straight answer, not an evasion.

  4. 4
    Generate solutions

    Give the 1530 antibiotic dose on time and acetaminophen per orders; cool the room, offer a cool shower or cool cloths and ice packs, and remove extra bedding. Resume baclofen on schedule and reconcile the home doses with the patient. Bed low, call light in reach, assist with every transfer; encourage fluids and timed voiding, recheck the post-void residual after the infection is treated. Explain to her, in her words: "Fever and heat make old MS damage show up again. Treating the infection and cooling you down usually brings this back to baseline within a day or two. If weakness is still there once the fever is gone, the neurologist will look for a new lesion on MRI, and steroids would be considered then." Document the baseline neuro exam precisely so the 48-hour comparison means something.

  5. 5
    Take action

    Act in that order: antibiotic at 1530, cooling measures started, baclofen resumed with the 1700 dose, fall precautions in place, timed voiding begun. Then the SBAR to the provider and the neurology consult: "34-year-old with RRMS, three days of worsening leg weakness, spasms, and right-eye blur; febrile to 38.3, tachycardic 104, urinalysis positive for nitrites and leukocytes with a 210 mL residual, no A/C for five days, and three to four missed baclofen doses. No eye-movement pain or afferent defect. First antibiotic dose given, cooling started, baclofen resumed. Will reassess neuro status every 4 hours and at 48 h; requesting parameters for re-escalation." The trap to avoid is the one she asked for: reaching for steroids because "new symptoms in MS means a relapse" — which is exactly the misdiagnosis that leads to inappropriate steroid treatment or an unneeded DMT switch.

  6. 6
    Evaluate

    Success by 48 hours: afebrile, heart rate down, dysuria settling, spasms easing on scheduled baclofen, and leg strength and vision back toward her baseline — the pseudo-relapse pattern. If instead the weakness or the visual blur persists after the fever and infection have cleared, this was a true relapse riding on the infection: the neurologist will image for gadolinium-enhancing lesions and consider high-dose steroids, with plasma exchange if the steroid response is poor. The re-escalation triggers are memorized in advance: seizures, hallucinations, or high fever with rigidity (baclofen withdrawal), confusion or flank pain with rising fever (the UTI ascending), and any new deficit that develops within minutes — which is not MS at all and is worked up as a stroke.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Medical unit · 1500, admitted from the ED during a July heat wave

A 34-year-old woman with relapsing-remitting MS for six years, on daily glatiramer injections and baclofen 10 mg three times daily for leg spasticity. Baseline: walks unaided, mild left-leg weakness, urinary urgency. For three days she has had worsening bilateral leg weakness and spasms, blurred vision in the right eye, burning with urination, and she "can barely get out of bed." Her air conditioner failed five days ago. In the ED she asked, "Is this a relapse? Don’t I need the steroids?"

1500 vitals — T 38.3 °C · HR 104 · BP 118/74 · RR 18 · SpO₂ 97% on room air
Neuro — bilateral lower-extremity weakness worse than baseline, spasms with clonus at both ankles (Modified Ashworth 3 on the left, 2 on the right); right-eye blur, no eye-movement pain, pupils equal and reactive, no afferent defect; alert, oriented, mildly slowed
Urinalysis — cloudy · nitrites positive · leukocyte esterase positive · many bacteria · WBC 12.8 × 10⁹/L; urine culture sent; bladder scan post-void residual 210 mL
Chart — glatiramer last given this morning; patient reports missing "three or four" baclofen doses over the weekend because "it made me sleepy in the heat"; ED gave IV fluids and acetaminophen; antibiotics ordered, first dose due 1530
Provider note — "New deficits in the setting of fever and UTI; will not start methylprednisolone; treat infection, cool, reassess neuro status at 48 h; neurology consult; MRI with gadolinium if deficits persist after infection resolves"
Q1 Select all that apply
Which findings support the provider’s decision to treat this as a pseudo-relapse rather than a true relapse? Select all that apply.
  1. A. Temperature 38.3 °C with positive nitrites and leukocyte esterase on urinalysis
  2. B. Five days of heat exposure after the air conditioner failed
  3. C. Symptoms have lasted three days
  4. D. Absence of pain on eye movement and no afferent pupillary defect with the right-eye blur
  5. E. Baseline left-leg weakness and urinary urgency
Reveal answer & rationale
Answer: A, B, D
The definition of a relapse requires new symptoms in the absence of fever or infection — so fever with a positive urinalysis (A) is the single strongest argument for pseudo-relapse. Heat exposure (B) is the classic Uhthoff trigger: a 0.2–0.5 °C rise in core temperature blocks conduction in demyelinated axons. A blur without eye-movement pain or an afferent defect (D) lacks the signature of a new optic neuritis, favoring unmasking of old damage. Duration of three days (C) does not discriminate — pseudo-relapses persist as long as the fever and infection do; the 24-hour rule separates a relapse from a fleeting Uhthoff episode, not from a pseudo-relapse. Her baseline deficits (E) describe the disease she already has and do not sort this event either way.
Q2 Multiple choice
The patient asks, "Why won’t they give me the steroids?" The nurse’s best response is:
  1. A. "Steroids are only used for optic neuritis, and your eye exam is normal."
  2. B. "With a fever and a urine infection, your symptoms are most likely old damage showing through; steroids would add infection risk and would not change your long-term outcome even in a true relapse."
  3. C. "Steroids prevent disability, so the team is saving them until the MRI confirms a new lesion."
  4. D. "Your disease-modifying injection is treating this; steroids are not needed on glatiramer."
Reveal answer & rationale
Answer: B
Response B states the two sourced truths: relapse is defined in the absence of fever or infection — so this is presumptively a pseudo-relapse whose treatment is the infection — and steroids speed recovery but do not alter long-term disability, while adding immunosuppression and toxicity. Option A is wrong: steroids treat any disabling relapse, not just optic neuritis. Option C repeats the killed myth that steroids prevent disability. Option D confuses roles: glatiramer reduces future relapses; it does not treat an acute event, and it does not exempt her from steroids if a true relapse is confirmed.
Q3 Put in order
Put the nurse’s first four actions in priority order:
  1. A. Resume scheduled baclofen and assess for withdrawal signs
  2. B. Give the first antibiotic dose on time and begin cooling measures
  3. C. Document a precise baseline neurological exam for the 48-hour comparison
  4. D. Institute fall precautions and a timed-voiding plan
Reveal answer & rationale
Correct order: B → A → D → C
The infection and the raised temperature are the cause of the deterioration and a trigger for a true relapse, so antibiotics and cooling come first (B). Missed baclofen is both a driver of the spasms and a withdrawal hazard — seizures and hallucinations — so restoring it is next (A). Then protect a weak, febrile patient with a 210 mL residual from falls and further urinary stasis (D). Documentation (C) is essential — the whole plan hinges on a 48-hour comparison — but it never precedes the actions that treat the cause and prevent harm.
Q4 Multiple choice
At 0200 the patient is found sweating, tremulous, and hallucinating, with rigid legs and a temperature of 39.4 °C despite the antibiotic. Which is the most likely explanation the nurse should report?
  1. A. An expected Uhthoff phenomenon from the fever
  2. B. A true MS relapse now declaring itself
  3. C. Baclofen withdrawal from the missed doses
  4. D. Interferon-type flu-like reaction to the morning injection
Reveal answer & rationale
Answer: C
Hallucinations, rigidity, and hyperpyrexia after several missed baclofen doses is the baclofen withdrawal picture — seizures and hallucinations with oral withdrawal, and hyperpyrexia, altered mental status, rigidity, and rebound spasticity in the severe form — an emergency (C). Uhthoff (A) causes transient sensory, visual, or motor worsening, not hallucinations or rigidity. A relapse (B) develops over days to weeks and does not produce fever or hallucinations. Glatiramer, not interferon, is her injection, and even interferon’s flu-like reaction runs 2–8 hours post-dose and resolves within 24 hours (D).
Q5 Select all that apply
Before discharge, which teaching points should the nurse include? Select all that apply.
  1. A. Report fever, burning, cloudy or bad-smelling urine, back or side pain, or a sudden rise in spasms promptly
  2. B. Avoid hot showers, baths and saunas, and exercise during the cooler parts of the day
  3. C. Skip vaccines while on glatiramer because they can trigger relapses
  4. D. Never stop baclofen on your own; call before missing doses if the sedation is a problem
  5. E. Rotate glatiramer injections among arms, abdomen, hips, and thighs
Reveal answer & rationale
Answer: A, B, D, E
Prompt reporting of UTI cues — including the atypical cue of more spasms (A) — matters because infection doubles relapse risk and drives pseudo-relapses. Avoiding hot showers, baths and saunas and exercising in the cooler early-morning or late-evening hours (B) are the standard Uhthoff measures. Abrupt baclofen stops cause seizures and hallucinations (D), so the dose is adjusted by the prescriber, not skipped. Site rotation (E) prevents lumps and lipoatrophy. Option C is the killed myth: vaccines are not associated with increased relapse risk (ECTRIMS/EAN 2023); people with MS are advised to keep vaccinations current, with live vaccines timed before DMTs that require it.

Common questions

What causes multiple sclerosis?
Common causes and risk factors include female sex — about 3-fold more common than in males, onset age 20–40 (rrms mean 25–29; ppms 39–41); almost 10% present before age 18, epstein-barr virus infection — 32-fold higher risk after seroconversion; likely a prerequisite for disease, compounded by severe infectious mononucleosis, hla-drb1*1501 allele — the most established genetic risk factor, first-degree relative with ms (2–4% risk vs 0.1% general population); monozygotic twin concordance 20–30%, and others.
What are the early signs of multiple sclerosis?
Early findings include Optic neuritis — monocular vision loss over hours to days, pain on eye movement, washed-out reds, relative afferent pupillary defect (RAPD), Numbness, pins-and-needles, dysesthesias, and a band-like squeeze around the chest or abdomen.
Which findings should a nurse report immediately in multiple sclerosis?
Report immediately: Deficits that develop within minutes, seizures, aphasia or neglect, onset before 10 or after 50, Progressive multifocal leukoencephalopathy (PML) on disease-modifying therapy, Baclofen withdrawal — abrupt stop. These signal deterioration that needs rapid intervention.
What is the difference between an MS relapse and a pseudo-relapse?
A relapse is new or worsening neurological symptoms lasting at least 24 hours, at least 30 days after the last event, without fever or infection — a new inflammatory lesion, often gadolinium-enhancing on MRI, treated with high-dose steroids if disabling. A pseudo-relapse is old symptoms flaring because of fever, infection, heat, or exertion: raised body temperature blocks conduction in already-demyelinated nerves. It improves when the cause is treated and cooled, and treating it with steroids or a change of disease-modifying therapy is inappropriate. Because infection also doubles the risk of a true relapse, a deficit that persists after the infection clears is re-evaluated as a relapse.
Do steroids cure or slow down multiple sclerosis?
No. High-dose methylprednisolone shortens a relapse — it speeds recovery of vision after optic neuritis, for example — but the final outcome and long-term disability are the same with or without steroids. Slowing the disease is the job of disease-modifying therapies, which reduce relapses and MRI activity when started promptly at diagnosis. Steroids are also held for pseudo-relapses, and low-dose oral prednisone alone can increase recurrent optic neuritis.
Why is heat so dangerous for someone with MS, and what helps?
Demyelinated axons conduct with almost no margin; a rise in core temperature of just 0.2–0.5 °C closes their sodium channels and blocks the signal, so hot weather, hot showers, saunas, fever, or exercise make old symptoms reappear — the Uhthoff phenomenon. It is not new damage: symptoms fade within minutes to an hour of cooling. Practical measures are lukewarm water for bathing, air conditioning, cold showers, ice packs or cooling garments, exercising in cooler times of day, avoiding saunas and hot tubs, and treating fever promptly.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.